These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

905 related articles for article (PubMed ID: 15619665)

  • 1. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
    Tsujisawa T; Inoue H; Nishihara T
    J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles.
    Wei X; Zhang X; Zuscik MJ; Drissi MH; Schwarz EM; O'Keefe RJ
    J Bone Miner Res; 2005 Jul; 20(7):1136-48. PubMed ID: 15940366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SC-19220, a prostaglandin E2 antagonist, inhibits osteoclast formation by 1,25-dihydroxyvitamin D3 in cell cultures.
    Inoue H; Tsujisawa T; Fukuizumi T; Kawagishi S; Uchiyama C
    J Endocrinol; 1999 May; 161(2):231-6. PubMed ID: 10320820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E2 strongly inhibits human osteoclast formation.
    Take I; Kobayashi Y; Yamamoto Y; Tsuboi H; Ochi T; Uematsu S; Okafuji N; Kurihara S; Udagawa N; Takahashi N
    Endocrinology; 2005 Dec; 146(12):5204-14. PubMed ID: 16150915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.
    Li X; Pilbeam CC; Pan L; Breyer RM; Raisz LG
    Bone; 2002 Apr; 30(4):567-73. PubMed ID: 11934647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs.
    Suzawa T; Miyaura C; Inada M; Maruyama T; Sugimoto Y; Ushikubi F; Ichikawa A; Narumiya S; Suda T
    Endocrinology; 2000 Apr; 141(4):1554-9. PubMed ID: 10746663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro.
    Li X; Okada Y; Pilbeam CC; Lorenzo JA; Kennedy CR; Breyer RM; Raisz LG
    Endocrinology; 2000 Jun; 141(6):2054-61. PubMed ID: 10830290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2.
    Ono K; Akatsu T; Murakami T; Nishikawa M; Yamamoto M; Kugai N; Motoyoshi K; Nagata N
    J Endocrinol; 1998 Sep; 158(3):R1-5. PubMed ID: 9846175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells.
    Nukaga J; Kobayashi M; Shinki T; Song H; Takada T; Takiguchi T; Kamijo R; Hasegawa K
    J Periodontol; 2004 Feb; 75(2):249-59. PubMed ID: 15068113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro.
    Tomita M; Li X; Okada Y; Woodiel FN; Young RN; Pilbeam CC; Raisz LG
    Bone; 2002 Jan; 30(1):159-63. PubMed ID: 11792579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective regulation of RNK-16 cell matrix metalloproteinases by the EP4 subtype of prostaglandin E2 receptor.
    Zeng L; An S; Goetzl EJ
    Biochemistry; 1996 Jun; 35(22):7159-64. PubMed ID: 8679543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
    Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
    Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.